Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Neoleukin Therapeutics

Nasdaq:NLTX
Snowflake Description

Excellent balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NLTX
Nasdaq
$405M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies using protein design technology. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • Neoleukin Therapeutics has significant price volatility in the past 3 months.
NLTX Share Price and Events
7 Day Returns
31.5%
NasdaqGM:NLTX
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
291.8%
NasdaqGM:NLTX
1.6%
US Biotechs
-9.1%
US Market
NLTX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Neoleukin Therapeutics (NLTX) 31.5% 3.9% -13.3% 291.8% -36.7% 32.7%
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • NLTX outperformed the Biotechs industry which returned 1.6% over the past year.
  • NLTX outperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
NLTX
Industry
5yr Volatility vs Market

Value

 Is Neoleukin Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Neoleukin Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $10.56.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Neoleukin Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Neoleukin Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:NLTX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-2.57
NasdaqGM:NLTX Share Price ** NasdaqGM (2020-03-27) in USD $10.56
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Neoleukin Therapeutics.

NasdaqGM:NLTX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:NLTX Share Price ÷ EPS (both in USD)

= 10.56 ÷ -2.57

-4.11x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Neoleukin Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Neoleukin Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Neoleukin Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:NLTX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.11x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-21.8%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Neoleukin Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Neoleukin Therapeutics's assets?
Raw Data
NasdaqGM:NLTX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $3.73
NasdaqGM:NLTX Share Price * NasdaqGM (2020-03-27) in USD $10.56
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:NLTX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:NLTX Share Price ÷ Book Value per Share (both in USD)

= 10.56 ÷ 3.73

2.83x

* Primary Listing of Neoleukin Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Neoleukin Therapeutics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Neoleukin Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Neoleukin Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Neoleukin Therapeutics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-21.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Neoleukin Therapeutics expected to grow at an attractive rate?
  • Unable to compare Neoleukin Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Neoleukin Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Neoleukin Therapeutics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:NLTX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:NLTX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -21.8%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:NLTX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:NLTX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 0 -161 2
2023-12-31 0 -108 2
2022-12-31 0 -70 3
2021-12-31 0 -58 3
2020-12-31 0 -50 3
2020-03-28
NasdaqGM:NLTX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -15 -69
2019-09-30 0 -21 -66
2019-06-30 0 -29 -22
2019-03-31 25 -19 -19
2018-12-31 25 -32 -32
2018-09-30 25 -33 -43
2018-06-30 25 -30 -40
2018-03-31 -49 -56
2017-12-31 -45 -50
2017-09-30 -42 -45
2017-06-30 -38 -41
2017-03-31 -36 -39

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Neoleukin Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Neoleukin Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:NLTX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Neoleukin Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:NLTX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -3.51 -3.40 -3.62 2.00
2023-12-31 -2.39 -2.13 -2.65 2.00
2022-12-31 -1.63 -1.03 -2.35 3.00
2021-12-31 -1.39 -0.80 -1.95 4.00
2020-12-31 -1.27 -0.70 -1.61 4.00
2020-03-28
NasdaqGM:NLTX Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -2.57
2019-09-30 -2.74
2019-06-30 -0.94
2019-03-31 -0.81
2018-12-31 -1.34
2018-09-30 -1.83
2018-06-30 -1.70
2018-03-31 -2.41
2017-12-31 -2.14
2017-09-30 -1.93
2017-06-30 -1.88
2017-03-31 -1.89

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Neoleukin Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Neoleukin Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Neoleukin Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Neoleukin Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Neoleukin Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Neoleukin Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Neoleukin Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Neoleukin Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Neoleukin Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Neoleukin Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:NLTX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -69.44 18.13 6.32
2019-09-30 0.00 -66.23 16.33 -4.96
2019-06-30 0.00 -22.09 11.09 2.39
2019-03-31 25.00 -19.17 12.98 22.39
2018-12-31 25.00 -31.59 14.74 32.79
2018-09-30 25.00 -42.97 18.08 50.78
2018-06-30 25.00 -39.81 17.21 48.52
2018-03-31 -56.49 16.42 41.00
2017-12-31 -50.18 14.85 36.27
2017-09-30 -45.16 13.21 32.84
2017-06-30 -41.47 11.75 30.52
2017-03-31 -38.61 10.06 29.28
2016-12-31 -37.00 9.26 28.38
2016-09-30 -31.42 7.60 24.18
2016-06-30 -28.31 6.68 21.73
2016-03-31 -22.16 6.02 16.11
2015-12-31 -21.86 5.54 15.80
2015-09-30 -24.29 5.37 18.20
2015-06-30 -25.54 5.13 19.83
2015-03-31 -26.21 5.03 20.77
2014-12-31 -23.82 4.30 18.08
2014-09-30 -21.01 3.49 14.51
2014-06-30 -19.45 2.80 12.21
2014-03-31 -16.41 2.09 8.91
2013-12-31 -14.94 1.78 7.60
2013-09-30 -7.72 1.64 5.67

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Neoleukin Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Neoleukin Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Neoleukin Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Neoleukin Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Neoleukin Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Neoleukin Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Neoleukin Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Neoleukin Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Neoleukin Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Neoleukin Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 6.466988920919E+17x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Neoleukin Therapeutics Company Filings, last reported 2 months ago.

NasdaqGM:NLTX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 141.69 0.00 143.09
2019-09-30 66.88 0.00 66.31
2019-06-30 72.33 0.00 72.70
2019-03-31 71.54 0.00 74.17
2018-12-31 72.67 0.00 76.93
2018-09-30 76.72 0.00 86.73
2018-06-30 90.68 0.00 102.14
2018-03-31 85.83 0.00 92.66
2017-12-31 98.89 0.00 108.09
2017-09-30 114.09 0.00 119.70
2017-06-30 124.61 0.00 131.28
2017-03-31 136.94 0.00 121.58
2016-12-31 144.66 0.00 103.06
2016-09-30 155.36 0.00 145.94
2016-06-30 92.09 0.00 66.56
2016-03-31 102.39 0.00 68.72
2015-12-31 108.42 0.00 74.48
2015-09-30 114.03 0.00 117.41
2015-06-30 25.81 0.00 29.03
2015-03-31 30.08 0.00 34.42
2014-12-31 36.15 0.00 39.10
2014-09-30 43.98 0.00 40.00
2014-06-30 50.02 0.00 35.89
2014-03-31 55.10 0.00 55.63
2013-12-31 8.97 2.29 13.83
2013-09-30 12.37 0.00 15.87
  • Neoleukin Therapeutics's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Neoleukin Therapeutics's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Neoleukin Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Neoleukin Therapeutics has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 12.1% each year.
X
Financial health checks
We assess Neoleukin Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Neoleukin Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Neoleukin Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Neoleukin Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of Neoleukin Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Neoleukin Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Neoleukin Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:NLTX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:NLTX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Neoleukin Therapeutics has not reported any payouts.
  • Unable to verify if Neoleukin Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Neoleukin Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Neoleukin Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Neoleukin Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Neoleukin Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Neoleukin Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Neoleukin Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Neoleukin Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Drachman
COMPENSATION $4,030,916
AGE 57
TENURE AS CEO 0.6 years
CEO Bio

Dr. Jonathan G. Drachman, also known as John, M.D., has been Strategic Advisor for Innovation at Seattle Genetics, Inc. since May 17, 2018. Dr. Drachman serves as the President and has been Chief Executive Officer at Neoleukin Therapeutics, Inc. (Formerly known as Aquinox Pharmaceuticals, Inc.) since August 08, 2019 and served as its Interim Chairman of the Board. Dr. Drachman was Chief Medical Officer and Executive Vice President of Research & Development at Seattle Genetics, Inc. since October 2013 until May 17, 2018, where he played a key role in the clinical development of Adcetris® and advancing the pipeline of antibody-drug conjugates and immuno-oncology drug candidates. He serves as Clinical Associate Professor of Medicine at the University of Washington in Seattle. He served as Senior Investigator in the Division of Research and Education and Medical Director of the Umbilical Cord Blood Program at the Puget Sound Blood Center. Dr. Drachman joined Seattle Genetics in November 2004 and leads the clinical development activities of a number of Seattle Genetics’ therapeutic programs. Dr. Drachman served as an Associate Professor in the Hematology Division, Department of Medicine at the University of Washington in Seattle from 1998 to 2004. Dr. Drachman served as Senior Vice President of Research and Translational Medicine at Seattle Genetics Inc. from May 2010 to October 2013. He served as Vice President of Early Clinical Development at Seattle Genetics Inc. from September 2008 to May 2010 and served as its Vice President of Translational Medicine until May 2010 and Senior Medical Director until September 2008. He has been Director of Harpoon Therapeutics, Inc., since September 2018 and brought Immuno-Oncology Expertise to its board. He has been a Director of Calithera Biosciences, Inc. since December 2013. Dr. Drachman serves as a Member of Scientific Advisory Board at Integra Ventures. Dr. Drachman received a B.A. in Biochemistry from Harvard University and an M.D. from Harvard Medical School. Dr. Drachman completed his residency in Internal Medicine and fellowship in Medical Oncology at the University of Washington in Seattle. Dr. Drachman has more than many years of academic research, clinical oncology and biotechnology experience. He has a proven track record as a successful R&D executive in the biotech industry, including substantial knowledge of oncology drug development and novel biologics.

CEO Compensation
  • Insufficient data for John to compare compensation growth.
  • John's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure of the Neoleukin Therapeutics management team in years:

0.5
Average Tenure
  • The average tenure for the Neoleukin Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

John Drachman

TITLE
CEO, President & Director
COMPENSATION
$4M
AGE
57
TENURE
0.6 yrs

David Baker

TITLE
Co-founder & Member of Scientific Advisory Board

Robert Ho

TITLE
CFO & Secretary
AGE
43

Leslie Aberman

TITLE
Vice President of Legal Affairs & Intellectual Property
TENURE
0.5 yrs

Carl Walkey

TITLE
Vice President of Corporate Development

Samantha Willing

TITLE
Vice President of People
TENURE
0.5 yrs

Daniel-Adriano Silva Manzano

TITLE
VP & Head of Research
Board of Directors Tenure

Average tenure and age of the Neoleukin Therapeutics board of directors in years:

0.6
Average Tenure
54
Average Age
  • The average tenure for the Neoleukin Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Todd Simpson

TITLE
Independent Chairman
COMPENSATION
$114K
AGE
58

John Drachman

TITLE
CEO, President & Director
COMPENSATION
$4M
AGE
57
TENURE
0.6 yrs

David Baker

TITLE
Co-founder & Member of Scientific Advisory Board
TENURE
0.3 yrs

Sean Nolan

TITLE
Independent Director
COMPENSATION
$105K
AGE
51
TENURE
5.1 yrs

Rusty Williams

TITLE
Independent Director
COMPENSATION
$69K
AGE
70
TENURE
0.6 yrs

Sarah Noonberg

TITLE
Independent Director
COMPENSATION
$68K
AGE
51
TENURE
0.6 yrs

M. Boyd

TITLE
Independent Director
COMPENSATION
$65K
AGE
39
TENURE
0.6 yrs

Goncalo Bernandes

TITLE
Member of Scientific Advisory Board
TENURE
0.3 yrs

Michael Dougan

TITLE
Member of Scientific Advisory Board
TENURE
0.3 yrs

Michael Levitt

TITLE
Member of Scientific Advisory Board
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
20. Dec 19 Buy Baker Bros. Advisors LP Company 20. Dec 19 20. Dec 19 3,017,542 $8.40 $25,347,353
20. Dec 19 Buy Jonathan Drachman Individual 20. Dec 19 20. Dec 19 119,047 $8.40 $999,995
11. Sep 19 Buy Jonathan Drachman Individual 09. Sep 19 11. Sep 19 250,000 $3.30 $781,747
08. Aug 19 Buy Baker Bros. Advisors LP Company 06. Aug 19 07. Aug 19 371,525 $3.15 $1,115,615
X
Management checks
We assess Neoleukin Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Neoleukin Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies using protein design technology. The company’s lead product candidate is NL-201, a computationally-designed de novo protein therapeutic for the treatment of IL-2/IL-15 cancer immunotherapy. It also engages in research activities for the treatment of autoimmunity and allergy. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Details
Name: Neoleukin Therapeutics, Inc.
NLTX
Exchange: NasdaqGM
Founded: 2003
$405,220,569
38,373,160
Website: http://www.neoleukin.com
Address: Neoleukin Therapeutics, Inc.
1616 Eastlake Avenue East,
Suite 360,
Seattle,
Washington, 98102,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM NLTX USA Common Stock Nasdaq Global Market US USD 07. Mar 2014
DB 6AP USA Common Stock Deutsche Boerse AG DE EUR 07. Mar 2014
Number of employees
Current staff
Staff numbers
36
Neoleukin Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 02:28
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/16
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.